probiotics improved the gut microbiota profile of a Alzheimer's disease model and alleviated neurodegeneration in the eye.

Alzheimer's disease (AD) is a progressive disease and one of the most common forms of neurodegenerative disorders. Emerging evidence is supporting the use of various strategies that modulate gut microbiota to exert neurological and psychological changes. This includes the utilisation of probiotics as a natural and dietary intervention for brain health. Here, we showed the potential AD-reversal effects of probiotics through feeding to our AD model. The administration of strains was able to rescue the rough eye phenotype (REP) seen in AD-induced , with a more prominent effect observed upon the administration of DR7 (DR7). Furthermore, we analysed the gut microbiota of the AD-induced and found elevated levels of . The administration of DR7 restored the gut microbiota diversity of AD-induced with a significant reduction in 's relative abundance, accompanied by an increase of and . Through functional predictive analyses, was predicted to be positively correlated with neurodegenerative disorders, such as Parkinson's, Huntington's and Alzheimer's diseases, while was negatively correlated with these neurodegenerative disorders. Altogether, our data exhibited DR7's ability to ameliorate the AD effects in our AD-induced . Thus, we propose that be used as a potential biomarker for AD.